Allogene Therapeutics Inc... (ALLO)
| Bid | 1.51 |
| Market Cap | 337.85M |
| Revenue (ttm) | 22.7K |
| Net Income (ttm) | -265.78M |
| EPS (ttm) | -1.32 |
| PE Ratio (ttm) | -1.18 |
| Forward PE | -1.39 |
| Analyst | Buy |
| Ask | 1.59 |
| Volume | 1,844,402 |
| Avg. Volume (20D) | 5,503,020 |
| Open | 1.55 |
| Previous Close | 1.56 |
| Day's Range | 1.51 - 1.69 |
| 52-Week Range | 1.32 - 4.45 |
| Beta | 1.02 |
About ALLO
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic ...
Analyst Forecast
According to 9 analyst ratings, the average rating for ALLO stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 478.78% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · seekingalpha.com
Allogene Therapeutics, Inc. (ALLO) Q4 2024 Earnings Call TranscriptAllogene Therapeutics, Inc. (NASDAQ:ALLO ) Q4 2024 Earnings Conference Call March 13, 2025 5:00 PM ET Company Participants Christine Cassiano - EVP, Chief Corporate Affairs & Brand Strategy Officer Da...
1 month ago · seekingalpha.com
Allogene: Assessing The Pipeline, Competitive Landscape, And OpportunitiesAllogene Therapeutics is developing allogeneic CAR-T cells for cancer and autoimmune diseases, offering off-the-shelf therapies that reduce costs and treatment times. Cema-cel, Allogene's leading prod...
1 month ago · seekingalpha.com
Allogene Therapeutics: Disrupting CAR-T With A Scalable ModelAllogene Therapeutics: Disrupting CAR-T With A Scalable Model